Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) experienced a significant stock price increase of over 40%, attributed to the positive results of its innovative drug, Aditinib (TY-9591), in a key Phase II clinical trial for EGFR mutation advanced non-small cell lung cancer (NSCLC) [1][2] Group 1 - The stock price rose by 37.9% to HKD 21.36, with a trading volume of HKD 1.664 billion [1] - Aditinib's Phase II clinical trial results were selected for a Mini Oral presentation at the WCLC 2025 conference, highlighting its potential in treating NSCLC patients with EGFR mutations and brain metastases [1][2] - The trial involved 257 patients with EGFR mutation NSCLC and brain metastases, with a mid-term analysis showing an intracranial objective response rate (iORR) of 92.8% for Aditinib compared to 76.1% for Osimertinib, indicating significant efficacy [2]

Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) experienced a significant stock price increase of over 40%, currently trading at 21.36 HKD, driven by the positive results of its innovative drug, Aiduotini (TY-9591), in a key Phase II clinical trial for EGFR mutation advanced non-small cell lung cancer (NSCLC) [1][2] Group 1: Clinical Trial Results - The key registration Phase II clinical trial (NCT05948813) for Aiduotini has been selected for a Mini Oral presentation at the WCLC 2025 conference, highlighting its importance in the medical community [1] - The trial is an open-label, multi-center, randomized controlled study focusing on NSCLC patients with EGFR mutations (L858R or 19Del) and brain metastases, comparing the efficacy and safety of Aiduotini (160mg once daily) against Osimertinib (80mg once daily) [1][2] - A total of 257 patients with EGFR mutation NSCLC and brain metastases were enrolled, with a mid-term analysis based on 224 patients showing an intracranial objective response rate (iORR) of 92.8% for the Aiduotini group compared to 76.1% for the Osimertinib group, with a statistically significant P-value of 0.0006 [2]

Core Insights - The article highlights the changes in the Hong Kong Stock Connect holdings, with notable increases and decreases in ownership percentages for various companies [1][2]. Group 1: Increased Holdings - Heng Rui Medicine (01276) saw the largest increase in ownership percentage, rising by 1.49% to a total of 13.84% [2]. - Kanglong Chemical (03759) experienced a 1.35% increase, bringing its ownership to 60.51% [2]. - Zhaoyan New Drug (06127) increased by 1.27%, reaching a holding of 43.70% [2]. - Other companies with significant increases include Junshi Biosciences (01877) at +1.24% (59.08%) and China Pacific Insurance (02601) at +1.20% (44.16%) [2]. Group 2: Decreased Holdings - Shandong Molong (00568) had the largest decrease, with a drop of 1.99% to 57.67% [2]. - Yisou Technology (02550) decreased by 0.99%, now holding 37.95% [2]. - Nanjing Panda Electronics (00553) saw a reduction of 0.98%, bringing its ownership to 42.65% [2]. - Other notable decreases include Kailai Ying (06821) at -0.95% (43.35%) and Meizhong Jiahe (02453) at -0.95% (32.06%) [2]. Group 3: Five-Day Changes - In the last five trading days, China Merchants Energy (01138) had the highest increase in ownership, up by 6.19% to 65.63% [3]. - Shandong Molong (00568) also saw a significant increase of 3.74% [3]. - Other companies with notable increases include Zhongchu Innovation (03931) at +3.62% (10.35%) and Youbao Online (02429) at +3.33% (17.38%) [3]. Group 4: Twenty-Day Changes - Over the past twenty days, Anjiren Food (02648) experienced the largest increase, up by 12.29% to 20.54% [4]. - China Merchants Energy (01138) also saw a significant increase of 9.07% [4]. - Other companies with notable increases include Yimai Sunshine (02522) at +7.70% (43.02%) and Lens Technology (06613) at +7.56% (13.64%) [4].

同源康医药-B(02410)发布公告，张森泉先生(张先生)已提出辞任本公司独立非执行董事(独立非执行董 事)以投放更多时间从事其他商业事务，自2025年9月15日起生效。辞任后，张先生不再担任董事会审计 委员会主席、董事会薪酬与考核委员会成员及提名委员会成员。 ...

智通财经APP讯，同源康医药-B(02410)发布公告，张森泉先生(张先生)已提出辞任本公司独立非执行董 事(独立非执行董事)以投放更多时间从事其他商业事务，自2025年9月15日起生效。辞任后，张先生不 再担任董事会审计委员会主席、董事会薪酬与考核委员会成员及提名委员会成员。 ...

格隆汇9月15日丨同源康医药-B(02410.HK)宣布，张森泉已提出辞任公司独立非执行董事以投放更多时 间从事其他商业事务，自2025年9月15日起生效。辞任后，张森泉不再担任董事会审计委员会主席、董 事会薪酬与考核委员会成员及提名委员会成员。 ...

TYK Medicines, Inc 浙江同源康醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2410） 董事名單與其角色和職能 浙江同源康醫藥股份有限公司董事會（「董事會」）成員如下。 執行董事 董事會設立四個委員會。下表提供各董事會成員所在委員會的成員資料。 | | 委員會 | | 薪酬與考核 | | | | --- | --- | --- | --- | --- | --- | | 董事 | | 審計委員會 | 委員會 | 提名委員會 | 科學委員會 | | 吳豫生博士 | | | M | C | C | | 李鈞博士 | | M | | | M | | 顧虹博士 | | | | | | | 蔣鳴昱博士 | | | | | | | 何超先生 | | | | | | | 朱向陽博士 | | | | | | | 冷瑜婷博士 | | M | C | M | | | 許文青博士 | | | | | M | | 沈秀華博士 | | | | | | 附註： C 有關董事會委員會主席 吳豫生博士 非執行董事 李鈞博士 顧虹博士 蔣鳴昱博士 何超先生 朱向陽博士 獨立非執行董事 冷瑜婷博士 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何意見，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 TYK Medicines, Inc 浙江同源康醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2410） 獨立非執行董事辭任 及 暫未能符合相關上市規則 浙江同源康醫藥股份有限公司（「本公司」）董事（「董事」）會（「董事會」）宣佈，張 森泉先生（「張先生」）已提出辭任本公司獨立非執行董事（「獨立非執行董事」）以 投放更多時間從事其他商業事務，自2025年9月15日起生效。辭任後，張先生不 再擔任董事會審計委員會主席、董事會薪酬與考核委員會成員及提名委員會成 員。張先生已確認，彼與董事會及本公司之間並無意見分歧，亦概無有關其辭任 的事宜須提請本公司股東或香港聯合交易所有限公司（「聯交所」）垂注。 董事會謹藉此機會對張先生於其任職期間作出的寶貴貢獻致以衷心感謝。 董事長、執行董事兼總裁 吳豫生博士 香港，2025年9月15日 2 暫未能符合相關上市規則項下規定 張先生辭任後，本公司 ...

Core Insights - The 2025 World Lung Cancer Conference (WCLC) in Barcelona focuses on advancements in lung cancer research, clinical diagnosis, and innovative therapies, serving as a key platform for global lung cancer treatment innovation [1] Group 1: Clinical Trial Overview - The key registration trial for the drug Aido Tini (TY-9591) by company Same Source Pharmaceutical-B (02410) was selected for a Mini Oral presentation at WCLC 2025, highlighting its significance in the field [1] - The trial is an open-label, multi-center, randomized controlled phase II study targeting NSCLC patients with EGFR mutations (L858R or 19Del) and brain metastases, comparing the efficacy and safety of Aido Tini (160mg daily) against Osimertinib (80mg daily) [2] Group 2: Efficacy Results - As of February 28, 2025, the study enrolled 257 patients, with a mid-term analysis of 224 patients showing an intracranial objective response rate (iORR) of 92.8% for Aido Tini compared to 76.1% for Osimertinib, with a statistically significant P-value of 0.0006 [2] - Investigator-assessed iORR for Aido Tini was 91.0% versus 75.2% for Osimertinib, with a P-value of 0.002, indicating strong efficacy [3] Group 3: Safety Profile - The incidence of grade ≥3 treatment-related adverse events was 31.5% for Aido Tini and 15.0% for Osimertinib, with common severe adverse reactions including elevated creatine phosphokinase and QTc interval prolongation [3] - The incidence of interstitial lung disease (ILD) was 6.3% and QTc prolongation was 4.5%, both within manageable limits [3] Group 4: Market Potential - Currently, there are no approved third-generation EGFR-TKIs for NSCLC with brain metastases, positioning Aido Tini as a promising candidate to meet the clinical needs of this patient population [4] - The recognition of Aido Tini's efficacy and safety data at an international academic conference underscores its potential for clinical translation and commercial success in a supportive policy environment for innovative drug development in China [4]

Core Insights - The 2025 World Lung Cancer Conference (WCLC) in Barcelona focuses on advancements in lung cancer research, clinical treatment, and innovative therapies, serving as a key platform for global lung cancer treatment innovation [1] Group 1: Clinical Trial Overview - The key registration trial for the drug Aido Tini (TY-9591) was selected for a Mini Oral presentation at WCLC 2025, highlighting its significance in the field [1] - The trial is an open-label, multi-center, randomized controlled phase II study comparing Aido Tini (160mg daily) to Osimertinib (80mg daily) in untreated EGFR mutation-positive NSCLC patients with brain metastases [2] - A total of 257 patients with EGFR mutation-positive NSCLC and brain metastases were enrolled by February 28, 2025, with a mid-term analysis based on 224 patients showing a high intracranial objective response rate (iORR) of 92.8% for Aido Tini compared to 76.1% for Osimertinib [2] Group 2: Efficacy and Safety Results - The investigator-assessed iORR for Aido Tini was 91.0%, while for Osimertinib it was 75.2%, with a statistically significant difference (P=0.002) [3] - According to RANO-BM criteria, the confirmed iORR was 90.1% for Aido Tini and 74.3% for Osimertinib (P=0.0023) [3] - The incidence of grade ≥3 treatment-related adverse events was 31.5% for Aido Tini and 15.0% for Osimertinib, with the most common severe adverse reactions including elevated creatine phosphokinase and QTc interval prolongation [3] Group 3: Market Potential and Implications - Currently, there are no approved third-generation EGFR-TKIs for NSCLC with brain metastases, positioning Aido Tini as a promising candidate to meet the clinical needs of this patient population [4] - The recognition of Aido Tini's efficacy and safety data at an international academic conference underscores its clinical translation potential [4] - With supportive policies for innovative drug development in China, Aido Tini is expected to establish a solid foundation for future commercialization [4]